Business research
The global Diabetic Foot Ulcers (DFUs) pipeline has been growing rapidly, with numerous companies working on novel therapies to treat this debilitating condition. According to a recent report by DelveInsight, there are 20+ key companies developing 25+ DFUs treatment therapies, with a focus on advancing the pipeline products from the
Business research
Innovate UK has announced a £1.2 million investment in projects aimed at accelerating innovation in digital cognitive assessments for dementia. This investment is part of Innovate UK's support for the Dame Barbara Windsor Dementia Goals, which is driving faster progress towards more personalised dementia treatments and tools
Clinical trials
Beta thalassemia is a genetic blood disorder that affects hemoglobin production, leading to anemia and other complications. The disorder is caused by mutations in the HBB gene, which codes for the beta-globin subunit of hemoglobin. There are several types of thalassemia, including beta thalassemia major, beta thalassemia intermedia, and beta
Clinical trials
IgA nephropathy (IgAN) is the most common primary glomerular disease that can progress to end-stage renal failure (ESRD), with a subset of patients experiencing rapid disease progression and renal failure within years if not treated. Recent advancements in the IgA Nephropathy pipeline have led to the development of innovative therapies,
Clinical trials
The global influenza pipeline landscape is a highly competitive space, with 120+ companies and 120+ pipeline drugs in development. DelveInsight's "Influenza Pipeline Insight 2025" report provides comprehensive insights into the pharmaceutical and biotechnology companies, therapies, and clinical trials involved in the development of treatments for influenza.
Clinical trials
DelveInsight's "Gout Pipeline Insight 2025" report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in the Gout pipeline landscape. The Gout Pipeline report covers the Gout Pipeline drug profiles, including clinical and nonclinical stage products, and highlights the inactive pipeline products in this space.
Clinical trials
The Attention Deficit Hyperactivity Disorder (ADHD) pipeline is bustling with activity, featuring 20+ companies and 22+ pipeline drugs in various stages of development. Supernus Pharmaceuticals Inc. recently announced a study to evaluate the efficacy and safety of SPN-812 (viloxazine extended release) in children 4 to 5 years of age with
Trademarks
A trademark application has been made for "HSOAC HOMELAND SECURITY OPERATIONAL ANALYSIS CENTER" by Kelly Hyndman, representing the U.S. Department of Homeland Security. The application, made available to the public on October 07, 2025, seeks to trademark the colors black, white, dark blue, and light blue as
Trademarks
Wolters Kluwer N.V., a leading global provider of software information and digital solutions for professionals, has filed a trademark application for the phrase "WHEN YOU HAVE TO BE RIGHT." The application, made available to the public on October 05, 2025, covers a wide range of goods and
Business research
As of October 20, 2025, DelveInsight's comprehensive Essential Tremor Pipeline Insight report highlights the dynamic pipeline landscape, featuring 7+ companies and 10+ pipeline drugs being developed for the treatment of essential tremor. The report provides an in-depth analysis of the pipeline therapies, including their mechanism of action, clinical
Trademarks
A trademark application has been filed for the "KAPPODO" brand, representing Mitsuboshi Co., Ltd., by Eunyoung Lee Monami Law Group PLLC. The application was made available to the public on September 25, 2025, and relates to various goods and services in the field of Japanese cuisine, cooking, foods
Trademarks
LinkedIn Corporation, through its lawyer Jason E. Garcia of REED SMITH LLP, has filed a trademark application with the United States Patent and Trademark Office (USPTO) for the phrase "THE NETWORK THAT WORKS FOR YOUR BUSINESS". The application was made available to the public on September 25, 2025.
